Association of inclusion body myositis with T cell large granular lymphocytic leukaemia

Brain

Volumn 139, Issue 5, 2016, Pages 1348-1360

  Greenberg, Steven A ^a,b   Pinkus, Jack L ^a   Amato, Anthony A ^a   Kristensen, Thomas ^c   Dorfman, David M ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

inclusion bodies; inclusion body myositis; inflammatory myopathy; neurooncology; T lymphocytes

Indexed keywords

BIOLOGICAL MARKER; CD16 ANTIGEN; CD5 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CD94 ANTIGEN; PROTEIN; PROTEIN TIA1; STAT3 PROTEIN; UNCLASSIFIED DRUG; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SMEAR; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CLONAL VARIATION; DERMATOMYOSITIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; INCLUSION BODY MYOSITIS; LARGE GRANULAR LYMPHOCYTE; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOSIS; MALE; MIDDLE AGED; MYOPATHY; POLYMYOSITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; T CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA; T LYMPHOCYTE RECEPTOR GENE; BLOOD; CASE CONTROL STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; CYTOLOGY; METABOLISM; MUSCLE; PATHOLOGY; SKELETAL MUSCLE; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD; BIOMARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LYMPHOCYTOSIS; MIDDLE AGED; MUSCLE, SKELETAL; MUSCLES; MYOSITIS, INCLUSION BODY; PROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 84966552282     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww024     Document Type: Article

References (52)

1. Allenbach Y, Chaara W, Rosenzwajg M, Six A, Prevel N, Mingozzi F, et al. Th1 response and systemic treg deficiency in inclusion body myositis. PLoS One 2014; 9: e88788
2. Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 2000; 123 (Pt 10): 2030-9.
3. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193-208.
4. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988a; 23: 168-73.
5. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantitation of T8 + cytotoxic and T8 + suppressor cells. Ann Neurol 1988b; 23: 493-9.
6. Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55: 1385-7.
7. Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 2010; 95: 1534-41.
8. Beck EH, Amato AA, Greenberg SA. Inclusion body myositis and chronic lymphocytic leukemia: a case series. Neurology 2014; 83: 98-9.
9. Bender A, Behrens L, Engel AG, Hohlfeld R. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 1998; 84: 86-91.
10. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418-24.
11. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-40.
12. Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev 2009; 8: 349-53.
13. Dimitri D, Benveniste O, Dubourg O, Maisonobe T, Eymard B, Amoura Z, et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain 2006; 129 (Pt 4): 986-95.
14. Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E, et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009; 183: 4792-9.
15. Fyhr IM, Moslemi AR, Mosavi AA, Lindberg C, Tarkowski A, Oldfors A. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J Neuroimmunol 1997; 79: 185-9.
16. Fyhr IM, Moslemi AR, Tarkowski A, Lindberg C, Oldfors A. Limited T-cell receptor V gene usage in inclusion body myositis. Scand J Immunol 1996; 43: 109-14.
17. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003; 100: 9452-7.
18. Herndler-Brandstetter D, Brunner S, Weiskopf D, van Rijn R, Landgraf K, Dejaco C, et al. Post-thymic regulation of CD5 levels in human memory T cells is inversely associated with the strength of responsiveness to interleukin-15. Hum Immunol 2011; 72: 627-31.
19. Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, Momose K, et al. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci 2014; 105: 342-6.
20. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120: 3048-57.
21. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-13.
22. Kristensen T, Larsen M, Rewes A, Frederiksen H, Thomassen M, Moller MB. Clinical relevance of sensitive and quantitative STAT3 mutation analysis using next-generation sequencing in Tcell large granular lymphocytic leukemia. J Mol Diagn 2014; 16: 382-92.
23. Lamy T, Liu JH, Landowski TH, Dalton WS, Loughran TP Jr. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3( + ) large granular lymphocyte leukemia. Blood 1998; 92: 4771-7.
24. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117: 2764-74.
25. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73: 408-18.
26. Lima M, Almeida J, Santos AH, dos Anjos Teixeira M, Alguero MC, Queiros ML, et al. Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3( + )/TCR-alphabeta( + ) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease. Am J Pathol 2001; 159: 1861-8.
27. Lindberg C, Oldfors A, Tarkowski A. Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. Eur J Immunol 1994; 24: 2659-63.
28. Lindberg C, Oldfors A, Tarkowski A. Local T-cell proliferation and differentiation in inflammatory myopathies. Scand J Immunol 1995; 41: 421-6.
29. Liu JH, Wei S, Lamy T, Li Y, Epling-Burnette PK, Djeu JY, et al. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 2002; 100: 1449-53.
30. Lundell R, Hartung L, Hill S, Perkins SL, Bahler DW. T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules. Am J Clin Pathol 2005; 124: 937-46.
31. Meresse B, Curran SA, Ciszewski C, Orbelyan G, Setty M, Bhagat G, et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med 2006; 203: 1343-55.
32. Morice WG, Kurtin PJ, Leibson PJ, Tefferi A, Hanson CA. Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia. Br J Haematol 2003; 120: 1026-36.
33. Muntzing K, Lindberg C, Moslemi AR, Oldfors A. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 2003; 58: 195-200.
34. O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. The alpha beta Tcell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. J Autoimmun. 1994; 7: 321-33.
35. Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, et al. Systematic characterization of human CD8 + T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001; 103: 281-90.
36. Onyema OO, Njemini R, Forti LN, Bautmans I, Aerts JL, De Waele M, et al. Aging-associated subpopulations of human CD8+ Tlymphocytes identified by their CD28 and CD57 phenotypes. Arch Gerontol Geriatr 2015; 61: 494-502.
37. Pandya JM, Fasth AE, Zong M, Arnardottir S, Dani L, Lindroos E, et al. Expanded T cell receptor Vbeta-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum 2010; 62: 3457-66.
38. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000; 164: 1148-52.
39. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5'-nucleotidase IA in inclusion body myositis. Ann Neurol 2013; 73: 397-407.
40. Posnett DN, Edinger JW, Manavalan JS, Irwin C, Marodon G. Differentiation of human CD8 T cells: implications for in vivo persistence of CD8 + CD28-cytotoxic effector clones. Int Immunol 1999; 11: 229-41.
41. Qiu ZY, Fan L, Wang L, Qiao C, Wu YJ, Zhou JF, et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol 2013; 6: 82
42. Rajala HL, Olson T, Clemente MJ, Lagstrom S, Ellonen P, Lundan T, et al. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica 2015; 100: 91-9.
43. Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist 2004; 9: 247-58.
44. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43KDa muscle protein in inclusion body myositis. PLoS One 2011; 6: e20266
45. Salajegheh M, Rakocevic G, Raju R, Shatunov A, Goldfarb LG, Dalakas MC. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 2007; 69: 1672-9.
46. Schrenk KG, Krokowski M, Feller AC, Bernhard V, Mugge LO, Oelzner P, et al. Clonal T-LGL population mimicking leukemia in Felty's syndrome-part of a continuous spectrum of T-LGL proliferations? Ann Hematol 2013; 92: 985-7.
47. Shah MV, Zhang R, Irby R, Kothapalli R, Liu X, Arrington T, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008; 112: 770-81.
48. Singleton TP, Yin B, Teferra A, Mao JZ. Spectrum of clonal large granular lymphocytes (LGLs) of alphabeta T Cells: T-Cell clones of undetermined significance, T-Cell LGL leukemias, and T-Cell immunoclones. Am J Clin Pathol 2015; 144: 137-44.
49. Sollid LM. Intraepithelial lymphocytes in celiac disease: license to kill revealed. Immunity 2004; 21: 303-4.
50. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28-and CD8+ CD57 + T cells and their role in health and disease. Immunology 2011; 134: 17-32.
51. Vallejo AN, Schirmer M, Weyand CM, Goronzy JJ. Clonality and longevity of CD4 + CD28null T cells are associated with defects in apoptotic pathways. J Immunol 2000; 165: 6301-7.
52. Weekes MP, Wills MR, Mynard K, Hicks R, Sissons JG, Carmichael AJ. Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57 + CD28-CD8+ T-cell population. Immunology 1999; 98: 443-9.